ISPOR - RWD30 Adverse Event Reporting of Marketed Biosimilar and Biological Monoclonal Antibody Cancer Treatments in the United States

Full Text

RWD30 Adverse Event Reporting of Marketed Biosimilar and Biological Monoclonal Antibody Cancer Treatments in the United States

Abstract

Authors

X. Xue B. Truong J. Qian

Back to Volume 26, Supplemental Issue 6S

Your browser is out-of-date

ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now